🔗 Share this article

An underground economy for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on communication apps, based on new investigations.

Experimental Drug Gaining Traction Via Social Media

The experimental drug, which is still in clinical trials, is being promoted by online personalities for its alleged weight-reducing properties. Followers are urged to contact these accounts directly for source information, while also obtaining discount codes.

Thriving Commerce on Messaging Platforms

Additionally, a robust market exists on Telegram, where groups with thousands of members share comparison photos, injection guides and claims of rapid UK delivery. Vendors promote the drug there before directing customers to other platforms for transactions.

Learning About Retatrutide

This medication is an investigational injection created by American pharmaceutical company Eli Lilly. The drug targets three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials suggest it could help individuals lose up to a quarter of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.

Medical Experts Express Concerns

Nevertheless, physicians and pharmacists have warned that the distribution of what is still an unlicensed drug in the United Kingdom is a cause for concern and could result in individuals administering products of uncertain source.

Some experts stated the demand for retatrutide could be connected to the increasing price of licensed weight loss treatments such as Mounjaro.

Legal Position and Implementation

Marketing retatrutide on social media or Telegram is prohibited in the UK, as it is an unapproved drug that cannot be marketed or distributed for human use under the Human Medicines Regulations 2012.

Some influencers attempt to circumvent the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but advertising and supply can still breach medicines, advertising, and customer regulations, risking fines, prosecution or prison.

Service Reaction and Content Removal

Based on the social media company, the platform has taken down violative material and prohibited associated keywords and search suggestions. The company said it was dedicated to keeping the service safe and investing in strengthening enforcement strategies.

Digital Marketplace Operations

Investigations also discovered groups with up to 9,000 participants marketing retatrutide using Telegram's built-in discovery tool, which operates like a public directory. Typing “retatrutide” instantly brings up channels with thousands of users, filled with photos of weight loss, positive reviews and detailed guides for preparing or injecting at residence.

After minutes of entering one group, a vendor shared WhatsApp details, where the majority of transactions take place. The seller provided an instruction manual and guaranteed delivery within two days. When questioned whether the substance was genuine, one vendor responded: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. Not one asked about weight, health issues or previous experience.

Item Details and Pricing

Within these communities, messages display dark colored packages with Royal Mail stickers, claiming to include fresh supplies. One message read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, prepared at home with sterile water, or pre-filled injectors usually priced at £160 for 20mg. When asked how long a pen should be used, sellers give conflicting responses ranging from a few weeks to “depends on your body”.

Platform Moderation and Safety Actions

A representative for Telegram stated it regularly moderated dangerous material on its service including content that encouraged the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“People are administering materials they can’t verify. Although the research behind this drug is sound, these online products may not include what they advertise,” stated a pharmacy expert, the director of pharmacy at a pharmacy service.

A medical professional of Asda Online Doctor connected the increase in interest to recent price rises for authorized weight-loss medications such as Mounjaro. “With costs rising, individuals are using online platforms. But counterfeit injections are extremely risky. You can’t be certain what’s contained or whether the environment they were produced in was sterile,” she said.

Her staff has previously encountered patients injured by self-injection from unverified sources. “We understand the frustration, but purchasing from Telegram or communication platforms is taking chances with your well-being,” stated the doctor. “These substances could be contaminated or improperly measured.”

Producer Position

A spokesperson from Eli Lilly said the substance was in third stage research studies and had not been reviewed or approved by any government authority anywhere in the world. “Therefore at this time no one can market [it] for human use,” they explained, noting that any item “falsely representing itself as a Lilly experimental product not yet approved … may subject users to possibly serious health risks”.